{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:45Z","timestamp":1792839765183,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jhep.2016.04.016","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T07:00:41Z","timestamp":1461999641000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":376,"title":["Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study"],"prefix":"10.1016","volume":"65","author":[{"given":"Pavel","family":"Bogomolov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Alexandrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Voronkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Macievich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia","family":"Kokina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Petrachenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian A.","family":"Lempp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.04.016_b0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0032-1323623","article-title":"Virology of hepatitis D virus","volume":"32","author":"Taylor","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.04.016_b0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3851\/IMP2598","article-title":"An update on HDV: virology, pathogenesis and treatment","volume":"18","author":"Alvarado-Mora","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.04.016_b0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11894-013-0365-x","article-title":"Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery","volume":"16","author":"Noureddin","year":"2014","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhep.2016.04.016_b0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1478-3231.2010.02408.x","article-title":"Hepatitis D revival","volume":"31","author":"Wedemeyer","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.04.016_b0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021576","article-title":"Virus: introduction and epidemiology","volume":"5","author":"Rizzetto","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2016.04.016_b0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/liv.12058","article-title":"Current management of delta hepatitis","volume":"33","author":"Rizzetto","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.04.016_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110143","article-title":"The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology","volume":"9","author":"Goyal","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.04.016_b0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11908-012-0307-z","article-title":"Treatment options for hepatitis delta virus infection","volume":"15","author":"Heidrich","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jhep.2016.04.016_b0045","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2036.2012.04993.x","article-title":"Meta-analysis: antiviral treatment for hepatitis D","volume":"35","author":"Triantos","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.04.016_b0050","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.04.016_b0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0060","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350501000603","article-title":"Two-year interferon therapy with or without ribavirin in chronic delta hepatitis","volume":"10","author":"Gunsar","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.04.016_b0065","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0070","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.27585","article-title":"Pegylated interferon therapy of chronic hepatitis D: in need of revision","volume":"61","author":"Rizzetto","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0075","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3851\/IMP2306","article-title":"Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials","volume":"17","author":"Lamers","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.04.016_b0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2036.2005.02542.x","article-title":"Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study","volume":"22","author":"Niro","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.04.016_b0085","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1097\/QAD.0000000000000417","article-title":"Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients","volume":"28","author":"Soriano","year":"2014","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2016.04.016_b0090","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/hep.27946","article-title":"Tenofovir for hepatitis delta","volume":"63","author":"Soriano","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1473-3099(15)00155-3","article-title":"The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta","volume":"15","author":"Rizzetto","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.04.016_b0100","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/cncr.28031","article-title":"Phase 1\/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma","volume":"119","author":"Yust-Katz","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2016.04.016_b0105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.04.016_b0110","series-title":"Nucleic acid polymers are efficient in blocking hepatitis delta virus entry in vitro. The Global Viral Hepatitis Summit","author":"Poutay","year":"2015"},{"key":"10.1016\/j.jhep.2016.04.016_b0115","unstructured":"Replicor homepage; 2015 [cited 2015 23.11.2015]; Available from: http:\/\/replicor.com\/."},{"key":"10.1016\/j.jhep.2016.04.016_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058340","article-title":"Proteoglycans act as cellular hepatitis delta virus attachment receptors","volume":"8","author":"Lamas Longarela","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.04.016_b0125","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"elife"},{"key":"10.1016\/j.jhep.2016.04.016_b0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2016.04.016_b0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.04.016_b0140","article-title":"Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice","author":"Vercauteren","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.04.016_b0145","series-title":"Analyse der fr\u00fchen Schritte der Hepatitis B Virus Infektion: Zell-Polarisierung, Differenzierung und Zell-assoziierte Heparansulfat-Proteoglykane als essentielle Faktoren f\u00fcr die Etablierung einer Hepatitis B Virus Infektion","author":"Schulze","year":"2008"},{"key":"10.1016\/j.jhep.2016.04.016_b0150","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/JVI.01902-09","article-title":"Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction","volume":"84","author":"Schulze","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2016.04.016_b0155","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.04.016_b0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2014.03.002","article-title":"Mouse models of hepatitis B and delta virus infection","volume":"410","author":"Dandri","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jhep.2016.04.016_b0165","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.26211","article-title":"Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts","volume":"58","author":"Schieck","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0175","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.04.016_b0180","series-title":"HBV\/HDV infection inhibition study using a human derived liver cell culture. OMZ study report 201","author":"Schulze","year":"2010"},{"key":"10.1016\/j.jhep.2016.04.016_b0185","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/JCM.00084-10","article-title":"Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics","volume":"48","author":"Mederacke","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2016.04.016_b0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jhep.2016.04.016_b0195","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10928-014-9363-3","article-title":"Viral kinetic modeling: state of the art","volume":"41","author":"Canini","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jhep.2016.04.016_b0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/135965350300800602","article-title":"Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase","volume":"8","author":"Colombatto","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.04.016_b0205","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"Snoeck","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.04.016_b0210","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1007\/s00216-015-8853-5","article-title":"Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na-taurocholate cotransporting polypeptide inhibitor","volume":"407","author":"Haag","year":"2015","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jhep.2016.04.016_b0215","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.cgh.2015.05.029","article-title":"Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome","volume":"13","author":"Keskin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.04.016_b0220","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jhep.2010.02.001","article-title":"Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV","volume":"52","author":"Wedemeyer","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.04.016_b0225","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2005.03.090","article-title":"Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes","volume":"129","author":"Glebe","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.04.016_b0235","unstructured":"Wooddell CI, Chavez D, Goetzmann JE, Guerra B, Peterson RM, Lee H, et al. Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg (ID32). In: Diseases AAftSoL, editor. The AASLD Liver Meeting; 2015; San Francisco: Hepatology; 2015."},{"key":"10.1016\/j.jhep.2016.04.016_b0240","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus","volume":"126","author":"Op den Brouw","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jhep.2016.04.016_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044900","article-title":"HBsAg inhibits IFN-alpha production in plasmacytoid dendritic cells through TNF-alpha and IL-10 induction in monocytes","volume":"7","author":"Shi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.04.016_b0250","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1128\/JVI.77.17.9511-9521.2003","article-title":"Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus","volume":"77","author":"Glebe","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2016.04.016_b0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0014-5793(01)03190-8","article-title":"Structural and functional characterization of a monoclonal antibody specific for the preS1 region of hepatitis B virus","volume":"509","author":"Pizarro","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhep.2016.04.016_b0260","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.27240","article-title":"Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype","volume":"61","author":"Vaz","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.04.016_b0265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1752-8062.2011.00272.x","article-title":"Bile acids regulate cardiovascular function","volume":"4","author":"Khurana","year":"2011","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jhep.2016.04.016_b0270","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/heartjnl-2013-304163","article-title":"Bile acids induce arrhythmias in human atrial myocardium\u2013implications for altered serum bile acid composition in patients with atrial fibrillation","volume":"99","author":"Rainer","year":"2013","journal-title":"Heart"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816301489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816301489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T06:43:20Z","timestamp":1655621000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816301489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0168827816301489"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726324644.793535774","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}